NCT01658839View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Travoprost ophthalmic solution, 0.004% (new formulation)

Travoprost ophthalmic solution, 0.004%, new formulation

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01658839 - Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients | Biotech Hunter | Biotech Hunter